Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
For primary hyperlipidemia. Sold as Livalo. Every FDA application for this active ingredient: 1 branded and 8 generic.
As of Nov 16, 2026, FDA lists 9 applications for Pitavastatin Calcium (sold as Livalo), first approved Aug 3, 2009, with 2 new uses approved and 0 published complete response letters.
First approved: Aug 3, 2009
Applications: 9
New uses approved: 2
Complete response letters: 0
Medicare spending, 2025: $112M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
LivaloDrugs with a new additional pediatric dosage indicated for the treatment of familial hypercholesterolemia. · Kowa Company, Ltd. · Jun 26, 2015 · Review report
LivaloDrugs with a new dosage indicated for the treatment of hypercholesterolemia and familial hypercholesterolemia. · Kowa Company, Ltd. · Feb 28, 2013
Clinical Trials
5 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA